ACHIEVE I: Ubrogepant Meets Endpoints for Acute Migraine ACHIEVE I: Ubrogepant Meets Endpoints for Acute Migraine

Phase 3 trial results show that two doses of oral ubrogepant, a novel CGRP-targeting medication, met the primary endpoints of decreasing acute migraine pain and symptoms compared with placebo.Medscape Medical News

Source: Medscape Medical News Headlines - April 23, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news